Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Proteostasis Therapeutics has extended its collaboration with Cystic Fibrosis Foundation Therapeutics (CFFT), to research, develop and commercialize therapeutic candidates to treat people with cystic fibrosis (CF) who have the most common CF mutation, ΔF508del.
Subscribe to our email newsletter
CFFT is the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
The extension will focus on moving the company’s lead compounds toward a development candidate in 2014.
It will also focus on the company’s ain of filing an investigational new drug (IND) application with the US Food and Drug Administration in 2015.
The deal will continue to focus on the development of small molecule proteostasis regulators that modulate protein homeostasis pathways within the cell to correct the folding, trafficking and functional activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
The preclinical results have showed that ability of compounds to increase functional activity in ?F508 human bronchial epithelial cells.
In addition, the company’s lead candidates have shown significant synergistic properties with existing clinical-stage corrector candidates, more than doubling maximal activity and providing a strong foundation for the potential of combination therapies.
Proteostasis Therapeutics chief scientific officer Markus Haeberlein said the company is happy to continue its collaboration with CFFT, which has supported some of the most innovative and successful research in the field.
"This extension represents an endorsement of our novel approach to correcting CFTR activity and of the preclinical results that we have generated during the past 18 months," Haeberlein said.